Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.

PloS one - 1 Jan 2011

Sibley Christopher R, Wood Matthew J A

Abstract excerpt

Parkinson's disease (PD) is a progressive neurological disorder affecting an estimated 5-10 million people worldwide. Recent evidence has implicated several genes that directly cause or increase susceptibility to PD. As well as advancing understanding of the genetic aetiology of PD these findings suggest new ways to modify the disease course, in some cases through genetic manipulation. Here we generated a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Cell Line
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Microscopy, Fluorescence

Share to Parkinson Disease

Share to Protein Serine-Threonine Kinases

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 22031823
DOI: 10.1371/journal.pone.0026194
PMCID: PMC3198729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.PMID 22031823Read ↗

Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.Semantic proximity Read ↗

Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.Semantic proximity Read ↗

Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative DiseasesSemantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.Semantic proximity Read ↗

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.Semantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing <i>in vivo</i> in CNSSemantic proximity Read ↗

A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease.Semantic proximity Read ↗

Allele-specific silencing of dominant disease genes.Semantic proximity Read ↗

In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.Semantic proximity Read ↗

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.Semantic proximity Read ↗

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.Semantic proximity Read ↗

Evidence for contribution of compound heterozygous variants in Wiskott-Aldrich syndrome like (<i>WASL</i>) gene for early onset Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.